Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 5

Aldosterone antagonism in heart failure

Authors Alan B Miller

Published 15 November 2007 Volume 2007:3(5) Pages 605—609

Download Article [PDF] 

Alan B Miller

Division of Cardiology, University of Florida/Jacksonville, FL, USA

Abstract: Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction. Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure. The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo. Very few of these patients were on standard therapy with beta blockade. Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone. These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.

Keywords: aldosterone, eplerenone, heart failure

Download Article [PDF]